Financial Data and Key Metrics Changes - The company reported total revenues of $37.7 million for Q1 2024, representing a year-over-year growth of 23% compared to $30.7 million in Q1 2023 [5][11] - Adjusted EBITDA for Q1 2024 was $7.5 million, a 96% increase from the previous year, resulting in a 20% margin of revenues [5][27] - Net income for Q1 2024 was $2.3 million or $0.04 per diluted share, compared to a net loss of $1.8 million or a loss of $0.04 per share in Q1 2023 [27] Business Line Data and Key Metrics Changes - The growth in revenues was primarily driven by increased sales of KEDRAB and CYTOGAM due to heightened demand in the US market [11][21] - Operating expenses totaled $12.7 million, an increase of approximately 9% over the prior year, aligned with expectations to support expanded commercial activities and the Phase 3 InnovAATe trial [12] Market Data and Key Metrics Changes - Nearly 70% of revenues in Q1 2024 were generated from the US market [26] - The company successfully launched BEVACIZUMAB KAMADA, a biosimilar to Avastin, in Israel, which is expected to contribute to revenue growth [22] Company Strategy and Development Direction - The company is focusing on expanding its biosimilar portfolio, with expectations of significant contributions to revenue from these products in the coming years [8][15] - The company is actively pursuing business development opportunities to add commercial products to its portfolio, which is anticipated to support growth beyond 2024 [7][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued momentum throughout 2024, raising full-year revenue guidance to between $158 million and $162 million and adjusted EBITDA guidance to between $28 million and $32 million [19][27] - The company is encouraged by the positive feedback from the FDA regarding its inhaled Alpha-1 Antitrypsin therapy program, which may lead to accelerated development [9][23] Other Important Information - The company ended Q1 2024 with approximately $48 million in cash, providing financial strength for growth and development opportunities [7] - The company is expanding its plasma collection capacity, with new centers being established in Texas [10] Q&A Session Summary Question: What is the main driver of the revenue increase? - The main driver for the revenue increase has been primarily CYTOGAM, with a successful relaunch and increased physician awareness contributing to growth [29] Question: Can you provide details on the biosimilar program? - The current biosimilar portfolio is expected to generate between $32 million to $36 million in revenues, with each product contributing $2 million to $4 million over time [15] Question: What are the dynamics of biosimilars in Israel? - The dynamics in Israel are similar to those in the US, with market share dependent on the timing of product approvals and the company's first-mover advantage [43] Question: What areas is the company pursuing for business development? - The company is evaluating multiple opportunities in plasma-derived and transplantation products, looking for commercial-stage products to fuel growth [44] Question: Can you elaborate on the revised statistical analysis plan for the inhaled AAT program? - The revised plan, based on positive FDA feedback, aims to reduce sample size requirements and has been submitted for review, with expected feedback in the second half of the year [47]

REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024. Kamada management will host an investment ...

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Financial Operator Greetings. Welcome to Kamada Ltd.'s Fourth Quarter and Full Year 2023 Earnings Conference Call. This time, all participants are in a listen-only mode. A question-and-answer session will follow the ...

Exhibit 99.1 Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability Rehovot, Israel, and Hoboken, NJ – March 6, 2024 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) N/A (Translation of Registrant's name i ...

Kamada Ltd. (NASDAQ:KMDA) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good day, ladies and gentlemen, and welcome to Kamada Ltd.'s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation ...

AS AT SEPTEMBER 30, 2023 TABLE OF CONTENTS Page | Condensed consolidated interim statements of financial position | 1 | | --- | --- | | Condensed consolidated interim statements of profit or loss and other comprehensive income | 2 | | Condensed consolidated interim statements of changes in equity | 3-5 | | Condensed consolidated interim statements of cash flows | 6-7 | | Notes to the condensed consolidated interim financial statements | 8-15 | | - - - - - - - - - - - | | i KAMADA LTD. CONDENSED CONSOLIDATED ...

Kamada Ltd. (NASDAQ:KMDA) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - CEO Chaime Orlev - CFO Conference Call Participants Annabel Samimy - Stifel Operator Greetings. Welcome to Kamada Ltd. Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being re ...

Exhibit 99.3 AS OF JUNE 30, 2023 TABLE OF CONTENTS | Consolidated Statements of Financial Position | 1 | | --- | --- | | Consolidated Statements of Profit or Loss and Other Comprehensive Income | 2 | | Consolidated Statements of Changes in Equity | 3-5 | | Consolidated Statements of Cash Flows | 6-7 | | Notes to the Interim Consolidated Financial Statements | 8-14 | | - - - - - - - - - - - | | Page i KAMADA LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | | | | | | | As of | | --- | --- | --- | --- | -- ...

Kamada Ltd. (NASDAQ:KMDA) Q1 2023 Results Earnings Conference Call May 24, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Chief Executive Officer Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings and welcome to the Kamada Ltd. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As ...